End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12 CNY | -1.23% | +0.67% | -23.86% |
Apr. 29 | PhiChem Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 28 | PhiChem Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 58% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.86% | 871M | - | ||
+17.73% | 66.69B | A- | ||
+1.61% | 49.2B | A- | ||
+16.33% | 41.24B | B+ | ||
+18.68% | 25.89B | A- | ||
+12.78% | 19.81B | C+ | ||
-21.87% | 15.86B | A- | ||
-10.29% | 15.23B | C+ | ||
+2.32% | 15.35B | B+ | ||
-22.30% | 13.36B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 300398 Stock
- Ratings PhiChem Corporation